June 5, 2014, Volume 14, Issue 11;
A new study presented at the 2014 AAN Annual Meeting calls into question the use of hyperosmolar therapy for treating intracerebral hemorrhage (ICH). In a review of outcomes from a registry of patients with ICH, investigators said those treated with hyperosmolar therapy experienced significantly worse outcomes than those who did not receive the treatment. Will these findings alter ICH care? What additional research is necessary to confirm these findings? In this video, see the answers to these and other questions in a panel discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD; Neurology Today Associate Editor Robert G. Holloway Jr., MD, MPH; Vladimir Hachinski, MD, professor of neurology and epidemiology at Western University in Ontario; and Jeffrey L. Saver, MD, director of stroke and vascular neurology at the University of California in Los Angeles.